SGLT2 INHIBITORS

/ SCIENCE, SOLUTIONS / By
  1. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
  2. SGLT2 inhibitors may predispose to ketoacidosis
  3. An update on the safety of SGLT2 inhibitors
  4. SGLT2 inhibitors: are they safe?
  5. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
  6. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence
  7. Possible adverse effects of SGLT2 inhibitors on bone
  8. Risks associated with SGLT2 inhibitors: an overview
  9. A review on the relationship between SGLT2 inhibitors and cancer
  10. SGLT2 inhibitors and the diabetic kidney
  11. SGLT2 inhibitors and mechanisms of hypertension
  12. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure
  13. An update on SGLT2 inhibitors for the treatment of diabetes mellitus
  14. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
  15. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus
  16. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
  17. Development of SGLT1 and SGLT2 inhibitors
  18. Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects
  19. SGLT2 inhibitors as a therapeutic option for diabetic nephropathy
  20. Effects of SGLT2 inhibitors on cardiovascular outcomes
  21. Effects of SGLT2 inhibitors on kidney and cardiovascular function
  22. SGLT2 inhibitors: their potential reduction in blood pressure
  23. Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
  24. SGLT2 inhibitors
  25. SGLT2 inhibitors: the latest “new kids on the block”!
  26. SGLT2 inhibitors in the treatment of type 2 diabetes
  27. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
  28. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
  29. SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
  30. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
  31. SGLT2 inhibitors: molecular design and potential differences in effect
  32. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
  33. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis
  34. Promise of SGLT2 inhibitors in heart failure: diabetes and beyond
  35. Pump, pipes, and filter: do SGLT2 inhibitors cover it all?
  36. SGLT2 inhibitors: benefit/risk balance
  37. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias?
  38. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of …
  39. Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30–50% of filtered glucose load in humans
  40. Metabolism of the failing heart and the impact of SGLT2 inhibitors
  41. SGLT2 inhibitors in the management of type 2 diabetes
  42. Acute kidney injury from SGLT2 inhibitors: potential mechanisms
  43. More evidence for SGLT2 inhibitors in heart failure
  44. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
  45. Mechanisms and evidence for heart failure benefits from SGLT2 inhibitors
  46. The potential role of SGLT2 inhibitors in the treatment of type 1 diabetes mellitus
  47. Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?
  48. SGLT2 inhibitors-induced electrolyte abnormalities: an analysis of the associated mechanisms
  49. Practical approach to initiating SGLT2 inhibitors in type 2 diabetes
  50. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
  51. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
  52. Are SGLT2 inhibitors ready for prime time for CKD?
  53. Optimising the benefits of SGLT2 inhibitors for type 1 diabetes
  54. SGLT2 inhibitors and the kidney: effects and mechanisms
  55. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
  56. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study
  57. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
  58. The renal effects of SGLT2 inhibitors and a mini-review of the literature
  59. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis
  60. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
  61. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus
  62. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
  63. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and …
  64. SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management
  65. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
  66. SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
  67. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
  68. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: basic mechanisms and therapeutic perspectives
  69. Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: a meta-analysis
  70. Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: the potential contribution to diabetes complications and cardiovascular disease
  71. Uric acid and the cardio‐renal effects of SGLT2 inhibitors
  72. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
  73. Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
  74. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
  75. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System
  76. Basic and clinical pharmaco-therapeutics of SGLT2 inhibitors: a contemporary update
  77. Renal effects of SGLT2 inhibitors: an update
  78. Adverse effects of SGLT2 inhibitors on bone health
  79. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
  80. SGLT2 inhibitors in Liver Patients
  81. Does lower limb amputation concern all SGLT2 inhibitors?
  82. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
  83. Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure
  84. SGLT2 inhibitors play a salutary role in heart failure via modulation of the mitochondrial function
  85. Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?
  86. The serendipitous story of SGLT2 inhibitors in heart failure: new insights from DECLARE-TIMI 58
  87. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
  88. Synthetic strategies toward SGLT2 inhibitors
  89. Class effects of SGLT2 inhibitors on cardiorenal outcomes
  90. Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations
  91. What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
  92. SGLT2 inhibitors in type 2 diabetes management: key evidence and implications for clinical practice
  93. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission
  94. SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
  95. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
  96. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors
  97. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
  98. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications
  99. Use of SGLT2 inhibitors for diabetes and risk of infection: analysis using general practice records from the NPS MedicineWise MedicineInsight program
  100. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials
  101. Safety of SGLT2 inhibitors in patients with diabetes mellitus
  102. Diabetic ketoacidosis with SGLT2 inhibitors
  103. SGLT2 inhibitors: cardiovascular benefits beyond HbA1c—translating evidence into practice
  104. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind …
  105. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non‐SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with …
  106. Acute kidney injury and adverse renal events in patients receiving SGLT2–inhibitors: a systematic review and meta-analysis
  107. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data
  108. SGLT2 inhibitors: β blockers for the kidney?
  109. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation
  110. SGLT2 inhibitors and diabetic ketoacidosis—a growing concern
  111. The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis
  112. SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in type 2 diabetes mellitus
  113. Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
  114. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis
  115. The expanding résumé of SGLT2 inhibitors
  116. SGLT2 inhibitors and risk of stroke in patients with type 2 diabetes: A systematic review and meta‐analysis
  117. Combination therapy with SGLT2 inhibitors for diabetic kidney disease
  118. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
  119. SGLT2 inhibitors in T2D and associated comorbidities—differentiating within the class
  120. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice
  121. Adoption of new glucose-lowering medications in the US—the case of SGLT2 inhibitors: nationwide cohort study
  122. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
  123. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
  124. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney …
  125. Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: Is low‐grade inflammation the neglected component?
  126. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
  127. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models
  128. Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care
  129. SGLT2 inhibitors: nephroprotective efficacy and side effects
  130. SGLT2 inhibitors through the windows of EMPA-REG and CANVAS trials: a review
  131. SGLT2 inhibitors–a potential treatment for Alport syndrome
  132. SGLT2 inhibitors and urinary tract infections
  133. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using …
  134. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes
  135. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding …
  136. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta‐analysis
  137. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: An updated meta‐analysis
  138. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
  139. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
  140. Clinical credence—SGLT2 inhibitors, diabetes, and chronic kidney disease
  141. Are SGLT2 inhibitors reasonable antihypertensive drugs and renoprotective?
  142. SGLT2 inhibitors: practical considerations and recommendations for cardiologists
  143. SGLT2 inhibitors‘ interaction with other renoactive drugs in type 2 diabetes patients: still a lot to learn
  144. Does metformin interfere with the cardiovascular benefits of SGLT2 inhibitors? Questions about its role as the cornerstone of diabetes treatment
  145. Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale …
  146. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes
  147. SGLT2 inhibitors and cardiovascular outcomes: current perspectives and future potentials
  148. Risk of amputations associated with SGLT2 inhibitors compared to DPP‐4 inhibitors: a propensity‐matched cohort study
  149. SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
  150. SGLT2 inhibitors–an insulin-independent therapeutic approach for treatment of type 2 diabetes: focus on canagliflozin
  151. SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia
  152. The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
  153. The role of the kidney and SGLT2 inhibitors in type 2 diabetes
  154. Weight loss variability with SGLT2 inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
  155. Regression of left ventricular hypertrophy with SGLT2 inhibitors
  156. Renoprotective effects of GLP1R agonists and SGLT2 inhibitors
  157. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center
  158. SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients
  159. Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
  160. Positioning SGLT2 inhibitors/incretin-based therapies in the treatment algorithm
  161. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models
  162. Mechanisms of protective effects of SGLT2 inhibitors in cardiovascular disease and renal dysfunction
  163. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis
  164. SGLT2 inhibitors: the star in the treatment of type 2 diabetes?
  165. ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease
  166. Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure
  167. Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
  168. Recommendations on the proper use of SGLT2 inhibitors
  169. Are SGLT2 inhibitors a targeted treatment for diabetic kidney disease?
  170. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review
  171. Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013–2018
  172. Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus
  173. SGLT2–inhibitors; more than just glycosuria and diuresis
  174. Effects of SGLT2 inhibitors on circulating stem and progenitor cells in patients with type 2 diabetes
  175. Generalizability of cardiovascular safety trials on SGLT2 inhibitors to the real world: implications for clinical practice
  176. SGLT2 inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
  177. Are the cardiorenal benefits of SGLT2 inhibitors due to inhibition of the sympathetic nervous system?
  178. The role of kidney in glucose homeostasis–SGLT2 inhibitors, a new approach in diabetes treatment
  179. Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus
  180. Cardiorenal protection: potential of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes
  181. Cardiovascular and renal benefits of SGLT2 inhibitors: a narrative review
  182. Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients
  183. CCS/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis
  184. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials
  185. Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and …
  186. Minireview: are SGLT2 inhibitors heart savers in diabetes?
  187. SGLT2 inhibitors in the real world: too good to be true?
  188. Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia
  189. Renoprotective effects of SGLT2 inhibitors: beyond glucose reabsorption inhibition
  190. Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization
  191. An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent
  192. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
  193. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors: identification of a molecular link between their actions to …
  194. Clinical implication of SGLT2 inhibitors in type 2 diabetes
  195. Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
  196. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
  197. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational …
  198. Benefits of SGLT2 inhibitors beyond glycemic control–a focus on metabolic, cardiovascular and renal outcomes
  199. The Effects of SGLT2 inhibitors on Lipid Metabolism
  200. Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
  201. Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media
  202. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
  203. The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes
  204. Are the benefits of SGLT2 inhibitors in heart failure and a reduced ejection fraction influenced by background therapy? Expectations and realities of a new standard of …
  205. Diabetic Agents, From Metformin to SGLT2 inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar
  206. Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
  207. Clinical characteristics of diabetic ketoacidosis in users and non-users of SGLT2 inhibitors
  208. SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
  209. Evolving understanding of cardiovascular protection by SGLT2 inhibitors: focus on renal protection, myocardial effects, uric acid, and magnesium balance
  210. Sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology
  211. SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan
  212. Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches
  213. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1, 3, 4-Thiadiazolylmethylphenyl glucoside congeners
  214. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics
  215. Discovery of non-glucoside SGLT2 inhibitors
  216. The role of SGLT2 inhibitors in managing type 2 diabetes
  217. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
  218. SGLT2–inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2–inhibitors in clinical practice
  219. How and why SGLT2 inhibitors should be explored as potential treatment option in diabetic retinopathy: clinical concept and methodology
  220. The design and synthesis of novel SGLT2 inhibitors: C-glycosides with benzyltriazolopyridinone and phenylhydantoin as the aglycone moieties
  221. SGLT2 inhibitors for diabetes: turning symptoms into therapy.
  222. The sweet spot: heart failure prevention with SGLT2 inhibitors
  223. SGLT2 inhibitors and incretin agents: associations with alanine aminotransferase activity in type 2 diabetes
  224. Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice
  225. Design of SGLT2 inhibitors for the treatment of type 2 diabetes: a history driven by biology to chemistry
  226. Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE
  227. Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors
  228. Reduction of cardiovascular risk and improved estimated glomerular filtration rate by SGLT2 inhibitors, including dapagliflozin, is consistent across the class: an …
  229. A new HPLC–MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy …
  230. SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
  231. SGLT2 inhibitors and risk of genitourinary infections
  232. Ipragliflozin and other sodium–glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data
  233. Update on SGLT2 inhibitors—new data released at the American Diabetes Association
  234. Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus
  235. Combination treatment of SGLT2 inhibitors and GLP-1 receptor agonists: symbiotic effects on metabolism and cardiorenal risk
  236. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem
  237. SGLT2 inhibitors: slowing of chronic kidney disease progression in type 2 diabetes
  238. An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials
  239. Fluorine‐Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 inhibitors for Type II Diabetes
  240. SGLT2 inhibitors and cancer: why further evidence is required
  241. Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes
  242. Efficacy and safety of SGLT2 inhibitors in patients with type 1 diabetes: a meta-analysis of randomized controlled trials
  243. … of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors
  244. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: a clinician’s guide
  245. SGLT2 inhibitors: reviving the sodium-hydrogen exchanger cardioprotection hypothesis?
  246. Sodium‐glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta‐analysis
  247. Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
  248. Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta‐analysis of randomized controlled trials
  249. SGLT2 inhibitors as add on therapy in type 2 diabetes: a real world study
  250. SGLT2 inhibitors and heart failure—clinical implications
  251. The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and …
  252. SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors in diabetes and microvascular complications: A Review
  253. When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy
  254. … -glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review
  255. SGLT2 inhibitors in type 2 diabetic patients with renal function impairment slows the annual renal function decline, in a real clinical practice
  256. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of …
  257. Synthesis and biological evaluation of SGLT2 inhibitors: gem-difluoromethylenated Dapagliflozin analogs
  258. SGLT2 inhibitors in people with and without T2DM
  259. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial …
  260. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors
  261. Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors
  262. SGLT2 inhibitors may offer benefit beyond diabetes
  263. Liraglutide as add‐on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind …
  264. Meta‐analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add‐on to metformin in type 2 …
  265. SGLT2 inhibitors and the Risk of Hospitalization for Fournier’s Gangrene: A Nested Case–Control Study
  266. Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
  267. Compelling evidence for SGLT2 inhibitors and GLP-1 receptor agonists as first-line therapy in patients with diabetes at very high/high cardiovascular risk
  268. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European …
  269. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
  270. The effect of SGLT2 inhibitors on cardiovascular events and renal function
  271. SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes
  272. Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk
  273. Facile synthesis of 1, 2, 3-triazole analogs of SGLT2 inhibitors by ‘click chemistry’
  274. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review
  275. How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Completed and …
  276. Type 2 diabetes, SGLT2 inhibitors, and glucose secretion
  277. Use of SGLT2 inhibitors during Ramadan: a survey of physicians’ views and practical guidance
  278. Euglycemic diabetic ketoacidosis: the clinical concern of SGLT2 inhibitors
  279. A fluorescent glucose transport assay for screening SGLT2 inhibitors in endogenous SGLT2-expressing HK-2 cells
  280. Pharmacokinetic/pharmacodynamic properties and clinical use of SGLT2 inhibitors in non-Asian and Asian patients with type 2 diabetes and chronic kidney disease
  281. SGLT2 inhibitors as add-on therapy to metformin for people with type 2 diabetes: a review of placebo-controlled trials in Asian versus non-Asian patients
  282. SGLT2 inhibitors and protection against pancreatic beta cell failure
  283. Global Mechanisms Proposed for Cardioprotective Effects of SGLT2 inhibitors
  284. C-Aryl glycoside inhibitors of SGLT2: exploration of sugar modifications including C-5 spirocyclization
  285. Synthesis and biological evaluation of C-glucosides with azulene rings as selective SGLT2 inhibitors for the treatment of type 2 diabetes mellitus: discovery of YM543
  286. SGLT2 inhibitors in Diabetic Kidney Disease
  287. The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update
  288. Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors
  289. Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient
  290. Lack of evidence for a harmful effect of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative …
  291. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2
  292. How does CREDENCE inform best use of SGLT2 inhibitors in CKD?
  293. Potential place of SGLT2 inhibitors in treatment paradigms for type 2 diabetes mellitus
  294. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes
  295. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis
  296. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
  297. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease?
  298. What next after metformin? Thinking beyond glycaemia: are SGLT2 inhibitors the answer?
  299. Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists
  300. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)
  301. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
  302. SGLT2 versus DPP4 inhibitors for type 2 diabetes
  303. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
  304. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: a systematic review and meta-analysis
  305. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
  306. Effects of incretin-based therapies and SGLT2 inhibitors on skeletal health
  307. 12-month effects of incretins versus SGLT2–inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 …
  308. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners
  309. The Multiple Effects of SGLT2 inhibitors Suggest Potential Benefit in COVID-19 Patients
  310. Sodium-glucose cotransporter 2 (SGLT2) inhibitors from natural products: discovery of next-generation antihyperglycemic agents
  311. Exploring sodium glucose co-transporter-2 (SGLT2) inhibitors for organ protection in COVID-19
  312. Evaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitus
  313. Recent developments of C-Aryl Glucoside SGLT2 inhibitors
  314. Are SGLT2 inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?
  315. Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview
  316. The kidney and type 2 diabetes mellitus: therapeutic implications of SGLT2 inhibitors
  317. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta …
  318. A paradigm shift in diabetes therapy—dapagliflozin and other SGLT2 inhibitors
  319. Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 inhibitors
  320. SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
  321. Role of SGLT2 inhibitors in patients with diabetes mellitus and heart failure
  322. SGLT2 inhibitors and cirrhosis: A unique perspective on the comanagement of diabetes mellitus and ascites
  323. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents
  324. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model
  325. Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
  326. … involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in …
  327. The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
  328. Sodium glucose co-transporter 2 (SGLT2) inhibitors as potential antidiabetic agents
  329. Organ protection beyond glycaemic control with SGLT2 inhibitors
  330. SGLT2 inhibitors, sodium and off-target effects: an overview
  331. Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective
  332. SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
  333. Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease
  334. SGLT2 inhibitors and amputation risk: Real-world data from a diabetes foot wound clinic
  335. A comparative safety review between GLP-1 receptor agonists and SGLT2 inhibitors for diabetes treatment
  336. SGLT2 inhibitors in Type 1 diabetes: is this the future?
  337. Promising diabetes therapy based on the molecular mechanism for glucose toxicity: usefulness of SGLT2 inhibitors as well as incretin-related drugs
  338. Communicating emerging risks of SGLT2 inhibitors—timeliness and transparency of medicine regulators
  339. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
  340. Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
  341. SCORED and SOLOIST: the next scores for SGLT2 inhibitors
  342. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME
  343. Sodium glucose cotransporter 2 (SGLT2) inhibitors across the spectrum of hypertension
  344. SGLT2 inhibitors might halt progression of diabetic nephropathy
  345. Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 inhibitors
  346. SGLT2 inhibitors race to enter type-2 diabetes market
  347. SGLT2 inhibitors: diabetic kidney disease and beyond
  348. … Effects of Sirtuin-1 and Its Downstream Effectors: Potential Role in Mediating the Heart Failure Benefits of SGLT2 (Sodium-Glucose Cotransporter 2) inhibitors
  349. Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients—the role of antidiabetic and antihypertensive medications
  350. Subtype‐dependent reporting of stroke with SGLT2 inhibitors: implications from a Japanese pharmacovigilance study
  351. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents
  352. SGLT2 inhibitors for prevention of cardiorenal events in people with type 2 diabetes without cardiorenal disease: A meta-analysis of large randomized trials and cohort …
  353. SGLT2 inhibitors and all‐cause mortality: a meta‐analysis of randomized controlled trials.
  354. Syntheses of SGLT2 inhibitors by Ni-and Pd-Catalyzed Fukuyama Coupling Reactions
  355. Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
  356. Diabetic ketoacidosis precipitated by therapy with antidiabetic agents SGLT2 inhibitors: two cases
  357. Drug–drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes …
  358. SGLT2 inhibitors—Sweet Success for Diabetic Kidney Disease?
  359. SGLT2 inhibitors versus DPP4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus
  360. SGLT2 inhibitors and the risk of diabetic ketoacidosis
  361. Design, synthesis and in vivo hypoglycemic activity of tetrazole-bearing N-glycosides as SGLT2 inhibitors
  362. Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study
  363. How many patients with type 2 diabetes meet the inclusion criteria of the cardiovascular outcome trials with SGLT2 inhibitors? Estimations from a population …
  364. Novel l-Xylose Derivatives as Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) inhibitors for the Treatment of Type 2 Diabetes
  365. Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 inhibitor Drugs
  366. Efficacy and safety of SGLT2 inhibitors in reducing glycated hemoglobin and weight in emirati patients with type 2 diabetes
  367. Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside inhibitors of SGLT2
  368. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism
  369. SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: an extensive review
  370. SGLT2 inhibitors across the Spectrum of Severity of CKD
  371. When insulin therapy fails: the impact of SGLT2 inhibitors in patients with type 2 diabetes
  372. Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?
  373. Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors
  374. The influence of long‐term administration of SGLT2 inhibitors on blood pressure at the office and at home in patients with type 2 diabetes mellitus and chronic kidney …
  375. Comparative risk of genital infections associated with SGLT2 inhibitors: A real-world retrospective cohort study
  376. Targeting Type 2 Diabetes with C-Glucosyl Dihydrochalcones as Selective Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: Synthesis and Biological Evaluation
  377. Efficacy of DPP‐4 inhibitors, GLP‐1 analogues, and SGLT2 inhibitors as add‐ons to metformin monotherapy in T2DM patients: a model‐based meta‐analysis
  378. Pharmacoeconomic evaluation of sodium-glucose transporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes
  379. Use of SGLT2 inhibitors during Ramadan: An expert panel statement
  380. CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents
  381. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
  382. … to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors
  383. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
  384. Association of SGLT2 inhibitors with outcomes in Type 2 diabetes with reduced and preserved left ventricular ejection fraction—Analysis from the CVD‐REAL 2 Study
  385. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
  386. Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans
  387. Can the combination of incretin agents and sodium-glucose cotransporter 2 (SGLT2) inhibitors reconcile the Yin and Yang of glucagon?
  388. SGLT2 inhibitors: expanding their Empire beyond diabetes
  389. SGLT2 inhibitors in development
  390. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis
  391. Use of SGLT2 inhibitors in diabetic renal transplant recipients: a mixed method exploratory exercise
  392. Recommendations on the proper use of SGLT2 inhibitors
  393. Optimization of triazoles as novel and potent nonphlorizin SGLT2 inhibitors
  394. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME
  395. Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors
  396. Effectiveness and Safety of SGLT2 inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2
  397. SGLT2 inhibitors: Emerging Roles in the Protection Against Cardiovascular and Kidney Disease Among Diabetic Patients
  398. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
  399. Diabetic ketoacidosis in patients treated with SGLT2 inhibitors: experience at a tertiary hospital
  400. SGLT2 inhibitors and the Mechanisms Involved in Weight Loss
  401. SGLT2 inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy
  402. Response to comment on Suissa. Lower risk of death with SGLT2 inhibitors in observational studies: real or bias? Diabetes Care 2018; 41: 6–10
  403. Clinical Influence of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors for Cardiovascular and Renal Points of View
  404. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG
  405. Acute Renal Failure, Ketoacidosis, and Urogenital Tract Infections with SGLT2 inhibitors: Signal Detection Using a Japanese Spontaneous Reporting Database
  406. Focused Updates: SGLT2 inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease
  407. SGLT2 inhibitors for genetic and acquired insulin resistance: Considerations for clinical use
  408. Discovery of Novel N-β-d-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) inhibitors for the Management of Hyperglycemia in …
  409. Further insights into SGLT2 inhibitors
  410. Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors
  411. SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
  412. Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of type 2 diabetes
  413. Design and synthesis of fluorescent SGLT2 inhibitors
  414. Identifying Risk Factors for Diabetic Ketoacidosis Associated with SGLT2 inhibitors: a Nationwide Cohort Study in the USA
  415. Will SGLT2 inhibitors prove to be a ‘multiple’gamechanger?
  416. Diuretic treatment of the patient with diabetes and heart failure. Role of SGLT2 inhibitors and similarities with carbonic anhydrase inhibitors
  417. When and for Whom Should We Use SGLT2 inhibitors in HFrEF?
  418. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control
  419. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents
  420. Efficacy and safety of SGLT2 inhibitors in type 1 diabetes after the introduction of an off-label use protocol for clinical practice
  421. Assessment of the benefit-risk balance of SGLT2 inhibitors: Commentary on a new’French paradox’.
  422. Beware ketoacidosis with SGLT2 inhibitors in latent autoimmune diabetes of the adult
  423. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure
  424. The efficacy and safety of SGLT2 inhibitors combined with ACEI/ARBs in the treatment of type 2 diabetes mellitus: A meta-analysis of randomized controlled studies
  425. SGLT2 inhibitors for type 2 diabetes
  426. SGLT2 inhibitors enter crowded diabetes space
  427. Renal and cardiac implications of sodium glucose cotransporter 2 (SGLT2) inhibitors: the state of the science
  428. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
  429. GLP-1 Receptor agonists and SGLT2 inhibitors for the treatment of type 2 diabetes: new insights and opportunities for cardiovascular protection
  430. Preventing diabetic renal disease: the potential reno-protective effects of SGLT2 inhibitors
  431. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis
  432. SGLT2 inhibitors: a narrative review of efficacy and safety
  433. SGLT2 inhibitors and the autonomic nervous system in diabetes: A promising challenge to better understand multiple target improvement
  434. Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes
  435. Remarkable improvement of glucose variability by Sodium–glucose cotransporter 2 (SGLT2) inhibitors using continuous glucose monitoring (CGM)
  436. Comment on Suissa. Lower Risk of Death With SGLT2 inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018; 41: 6–10
  437. Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection …
  438. 1224-P: Improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice
  439. SGLT2 inhibitors and thiazide enhance excretion of DEHP toxic metabolites in subjects with type 2 diabetes: A randomized clinical trial
  440. Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
  441. SGLT2 inhibitors in Resistant Hypertension: A Sweet Solution
  442. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent
  443. SGLT2 inhibitors and renal complications in type 1 diabetes
  444. Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition
  445. The SGLT2 inhibitors–where are we now?
  446. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
  447. SGLT2 inhibitors: the Gift that Keeps on Giving
  448. Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly
  449. Safety of SGLT2 inhibitors. A review of the adverse drug reactions registered in a national database
  450. SGLT2 inhibitors: Who Should Prescribe Them for Patients With Heart Failure?
  451. Biomarker evidence for distal tubular damage but cortical sparing in hospitalized diabetic patients with acute kidney injury (AKI) while on SGLT2 inhibitors
  452. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled …
  453. The Pleiotropic Effects of SGLT2 inhibitors: Remodeling the Treatment of Heart Failure
  454. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose‐lowering drugs in patients with type 2 diabetes mellitus to prevent …
  455. SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews
  456. Potential role of SGLT2 inhibitors in the management of type 1 diabetes
  457. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and cardiovascular disease: a systematic review
  458. Effect of sodium glucose cotransporter 2 inhibitors with low SGLT2/SGLT1 selectivity on circulating glucagon-like peptide 1 levels in type 2 diabetes mellitus
  459. Role of metformin, Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and orlistat based multidrug …
  460. SGLT2 inhibitors and euglycemic diabetic ketoacidosis
  461. Repurposing SGLT2 inhibitors
  462. Chances and risks of SGLT2 inhibitors
  463. Atom-based 3D QSAR studies on novel N-β-d-xylosylindole derivatives as SGLT2 inhibitors
  464. Sodium glucose co transporter 2 (SGLT2) inhibitors: a new sword for the treatment of type 2 diabetes mellitus
  465. We Can Finally Stop Worrying About SGLT2 inhibitors and Acute Kidney Injury
  466. Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs
  467. Are the antidiabetic SGLT2 inhibitors a cardiovascular treatment?
  468. Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors
  469. SGLT2–inhibitors trigger downstream mechanisms that may exert adverse effects upon bone
  470. Use of SGLT2 inhibitors in Older Adults: Scientific Evidence and Practical Aspects
  471. Bolstering your armamentarium with SGLT2 inhibitors
  472. Unsweetening the heart: possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects
  473. Combined HQSAR, topomer CoMFA, homology modeling and docking studies on triazole derivatives as SGLT2 inhibitors
  474. A Systematic Review of Analytical Profiles of SGLT2 inhibitors and their Combinations for Treatment of Type 2 Diabetes Mellitus
  475. Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2–inhibitors and glp1-receptor agonists
  476. … and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of …
  477. Why Choose Between SGLT2 inhibitors and GLP1-RA When You Can Use Both? The Time to Act Is Now
  478. SGLT2 inhibitors: glucotoxicity and tumorigenesis downstream the renal proximal tubule?
  479. Synthesis of Benzyl C‐Analogues of Dapagliflozin as Potential SGLT2 inhibitors
  480. Syntheses of C-5-spirocyclic C-glycoside SGLT2 inhibitors
  481. Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors
  482. Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis
  483. Effects of SGLT2 inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes
  484. SGLT2 inhibitors Therapy in Type 2 Diabetes Mellitus
  485. Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening
  486. When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease
  487. … causes an increase in endog-enous glucose production (EGP). However, the mechanisms are unclear. We studied the effect of SGLT2 inhibitors on EGP in …
  488. Development of sodium glucose co-transporter 2 (SGLT2) inhibitors with novel structure by molecular docking and dynamics simulation
  489. SGLT2 inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database
  490. P1010 EFFECTS OF SGLT2 inhibitors ON DIABETIC NEPHROPATHY: PODOCYTURIA ON FOCUS
  491. Insight into the interaction mechanism of human SGLT2 with its inhibitors: 3D-QSAR studies, homology modeling, and molecular docking and molecular dynamics …
  492. Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
  493. The effect of SGLT2 inhibitors on silent myocardial ischemia
  494. Palladium‐Catalyzed Arylation of Carbasugars Enables the Discovery of Potent and Selective SGLT2 inhibitors
  495. In type 2 diabetes, SGLT2 inhibitors were linked to diabetic ketoacidosis vs. DPP-4 inhibitors
  496. Synthetic and biological studies of carbasugar SGLT2 inhibitors
  497. Glucosides with cyclic diarylpolynoid as novel C-aryl glucoside SGLT2 inhibitors
  498. Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis
  499. Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials
  500. Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors?
  501. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
  502. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2
  503. Development and recent advancement of SGLT2 inhibitors for the treatment regime of T2DM
  504. UNDER-PRESCRIPTION OF SGLT2 inhibitors IN PATIENTS WITH DIABETES AND CARDIOVASCULAR DISEASE IN THE UNITED STATES
  505. The future is now: SGLT2 inhibitors and type 1 diabetes–What about exercise?
  506. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review …
  507. SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies
  508. Design, synthesis and biological activity of cyclohexane-bearing C-glucoside derivatives as SGLT2 inhibitors
  509. The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation
  510. A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
  511. EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR …
  512. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study
  513. Risk of Cardiovascular Outcomes in Type 2 Diabetes Patients Following Addition of SGLT2 inhibitors Versus Sulfonylureas to Baseline GLP-IRA Therapy
  514. 5a-Carba-β-d-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
  515. SGLT2 inhibitors in diabetes mellitus treatment
  516. Possible new inflammatory side-effect of SGLT2–inhibitors: fixed drug eruption
  517. Recent and emerging therapeutic medications in type 2 diabetes mellitus: incretin-based, pramlintide, colesevelam, SGLT2 inhibitors, tagatose, succinobucol
  518. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2–inhibitors: a review
  519. SGLT2 inhibitors: the Gift that Keeps on Giving
  520. Sodium Glucose Co-Transporter-2 (SGLT2) inhibitors and The Risk of Diabetic Ketoacidosis: An Example of Complementary Evidence for Rare Adverse Events
  521. Correction to “Synthetic Strategies toward SGLT2 inhibitors”
  522. Renal hemodynamic and protective effects of renoactive drugs in type 2 diabetes: interaction with SGLT2 inhibitors.
  523. Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?
  524. Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors
  525. P1038 NEPHROPROTECTIVE EFFECT OF SGLT2 inhibitors DURING FIRST YEAR OF TREATMENT
  526. The efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors for the treatment of chronic diabetic macular oedema in vitrectomised eyes: a retrospective study
  527. Heart Failure Prevention with SGLT2 inhibitors
  528. Are SGLT2 inhibitors or GLP-1 receptor agonists more appropriate as a second-line therapy in type 2 diabetes?
  529. 1124-P: SGLT2 inhibitors as Adjuvant Therapy for Type 1 Diabetes: An Italian Center Experience
  530. A rose by any other name: ketoacidosis due to SGLT2 inhibitors reveals latent autoimmune diabetes
  531. The EMPEROR-Reduced trial: SGLT2 inhibitors for heart failure get more support
  532. Drugs for diabetes: part 8 SGLT2 inhibitors
  533. Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study
  534. C-Aryl 5a-carba-β-D-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes
  535. SGLT2 inhibitors-moving on with the evidence.
  536. … now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement …
  537. Optimization of Gaussian Kernel Function in Support Vector Machine aided QSAR studies of C-aryl glucoside SGLT2 inhibitors
  538. Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors
  539. Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and …
  540. Effects of SGLT2 inhibitors as an Add-on Therapy to Metformin on Electrocardiographic Indices of Ventricular Repolarization
  541. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus
  542. SGLT2 inhibitors suppress NLRP3 inflammasome activity via changes in ketones and insulin in type 2 diabetes and cardiovascular diseases
  543. Predicting the biological activities of triazole derivatives as SGLT2 inhibitors using multilayer perceptron neural network, support vector machine, and projection …
  544. Thiadiazole‐based Thioglycosides as Sodium‐glucose Co‐transporter 2 (SGLT2) inhibitors
  545. Heart Failure Endpoints in Cardiovascular Outcome Trials of SGLT2 inhibitors in Patients with Type 2 Diabetes: A Critical Evaluation of Clinical and …
  546. Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2
  547. SGLT2 inhibitors and sleep apnea; how helpful are the medications: A meta-analysis
  548. Conformationally Constrained Spiro C‐Arylglucosides as Potent and Selective Renal Sodium‐Dependent Glucose Co‐transporter 2 (SGLT2) inhibitors
  549. Mechanistic evaluation of the effect of SGLT2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems …
  550. … of type 2 diabetes mellitus with the development of new-onset atrial fibrillation in patients with non-ischemic dilated cardiomyopathy: impact of SGLT2 inhibitors
  551. 1097-P: Disposition Index Is a Predictor of Urinary Glucose Excretion in Subjects Treated with SGLT2 inhibitors
  552. Biochemical Interaction Analysis of Natural SGLT2 inhibitors with Alzheimer Targets: A Computational Approach.
  553. Essentials of SGLT2 inhibitors in Diabetes
  554. … with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, SGLT2 inhibitors and long-acting GLP-1 …
  555. … Background between Patients with and without Increased Glucagon Secretion while on SGLT2 inhibitors: A Comparison of Canagliflozin and Other SGLT2 inhibitors
  556. P2484 SGLT2 inhibitors in diabetes with CKD
  557. Sodium glucose transporter 2 (SGLT2) inhibitors: Current status in clinical practice.
  558. Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 inhibitors
  559. Integrated computational approach on sodium-glucose co-transporter 2 (SGLT2) inhibitors for the development of novel antidiabetic agents
  560. The Effects of SGLT2 inhibitors on Lipid Metabolism. Metabolites 2021, 11, 87
  561. Sodium-glucose linked transporter 2 (SGLT2) inhibitors—fighting diabetes from a new perspective
  562. SGLT2 inhibitors in patients with cirrhosis and diabetes mellitus: A tertiary center cohort study and insights about a potential therapeutic target for portal hypertension
  563. Real-World Clinical Experience with SGLT2 inhibitors: Use of Special Screening Tool for Type 2 Diabetes Patients to Avoid Serious Adverse Events: A Single-Centre …
  564. P1047 URICOSURIA AND URINARY GLUCOSE EXCRETION ON DIABETIC KIDNEY DISEASE (DKD) PATIENTES TREATED WITH SGLT2 inhibitors
  565. Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV
  566. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors
  567. SGLT2 inhibitors: a new generation of antidiabetic drugs
  568. C-Aryl glucosides substituted at the 4′-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type …
  569. Design, synthesis and in vivo anti-hyperglycemic activity of gem-dimethyl-bearing C-glucosides as SGLT2 inhibitors
  570. Do SGLT2 inhibitors Act Only Through a Functional Tubuloglomerular Feedback Induced by the Increased Outflow of Sodium?
  571. Acidosis without marked hyperglycemia: Euglycemic diabetic ketoacidosis associated with SGLT2–inhibitors
  572. Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases
  573. How low do we fall to lower hemoglobin A1c? SGLT2 inhibitors: Effective drugs or expensive toxins!
  574. SGLT2 inhibitors and the changing landscape for treatment of diabetes
  575. Patient and clinical characteristics of heart failure patients concomitantly prescribed SGLT2 inhibitors and sacubitril/valsartan, a database cohort study using the …
  576. Euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT2 inhibitors
  577. 1145-P: SGLT2 inhibitors Improve Day-to-Day Glucose Variability in Patients with Type 1 Diabetes
  578. Glucosuria Interferes With Measurement of Effective Renal Plasma Flow Using para-Aminohippuric Acid, With a Focus on SGLT2 inhibitors
  579. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis
  580. Cardiovascular benefit of SGLT2 inhibitors in the therapeutics of diabetes mellitus: A close look beyond the horizon
  581. Fournier’s Gangrene and Diabetic Ketoacidosis Associated with Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: Life-Threatening Complications
  582. A new and improved process for C-aryl glucoside SGLT2 inhibitors
  583. Are the protective effects of SGLT2 inhibitors a” class-effect” or are there differences between agents?
  584. The role of SGLT2 inhibitors in type 2 diabetes
  585. Risk of DKA with SGLT2 inhibitors
  586. SGLT2 inhibitors for treatment of type 2 diabetes mellitus: Focus on canagliflozin
  587. The Role of SGLT2 inhibitors in Vascular Aging
  588. Effects of SGLT2 inhibitors on Insulin Secretion and Insulin Resistance—Results from a Cross-Sectional Study
  589. Clinical and Economic Rationale for the Early use of SGLT2 inhibitors in Patients with Type 2 Diabetes
  590. Sweet success? SGLT2 inhibitors and diabetes
  591. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
  592. SGLT2 inhibitors for type 2 diabetes mellitus treatment
  593. PDB7 DIABETIC COMPLICATIONS ASSOCIATED WITH SGLT2 AND DPP4 inhibitors: A REAL-WORLD APPROACH
  594. 141-LB: The Reality of Diabetic Ketoacidosis in Patients with Type 2 Diabetes Using SGLT2 inhibitors Revealed by a Nationwide Claim-Based Database in Japan
  595. Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
  596. SGLT2 inhibitors: cardiovascular benefits beyond glycemic control
  597. P1009 RENAL OUTCOMES IN DIABETIC KIDNEY PATIENTS TREATED WITH GLP1 AGONIST RECEPTORS VS SGLT2 inhibitors
  598. Efficacy and cardiovascular safety of SGLT2 inhibitors.
  599. A mechanistic rationale for the investigation of SGLT2 inhibitors in HFpEF-Letter regarding the article’Baseline Characteristics of Patients with Heart Failure with …
  600. Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis
  601. Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A …
  602. Can CMR Elucidate the Cardiovascular Benefit of SGLT2 inhibitors?
  603. SGLT2 inhibitors and the Risk of Major Adverse Cardiovascular Events: A Multi-database Study Using a Prevalent New-User Design
  604. β-Selective C-Arylation of Silyl Protected 1,6-Anhydroglucose with Arylalanes: The Synthesis of SGLT2 inhibitors
  605. SGLT2 inhibitors and cardiovascular outcomes: Do they differ or there is a class effect? New insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study.
  606. A paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors.
  607. Safety of sodium-glucose cotransporter 2 inhibitors (SGLT2-I) during the month of Ramadan in Muslim patients with type 2 diabetes
  608. Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) inhibitors in Type 2 Diabetes Mellitus
  609. SGLT2 inhibitors: A Review of Canagliflozin
  610. … -P: Effect of Raised Alanine Transaminase (ALT) Levels on HbA1c in the Association of British Clinical Diabetologists (ABCD) Nationwide Audits of SGLT2 inhibitors …
  611. Should we be combining GLP-1 receptor agonists and SGLT2 inhibitors in treating diabetes?
  612. Diabetic ketoacidosis without hyperglycemia as a complication of SGLT2 inhibitors treatment
  613. SGLT2–inhibitors in type-2 diabetes: The remaining questions!
  614. 36-OR: Comparative effectiveness of SGLT2 inhibitors vs. GLP-1 agonists
  615. SGLT2 inhibitors and euglycemic ketoacidosis
  616. SGLT2 inhibitors: not just another glucose-lowering agent
  617. Synthesis and biological evaluation of benzocyclobutane-C-glycosides as potent and orally active SGLT1/SGLT2 dual inhibitors
  618. SGLT2 inhibitors suppress alpha-adrenergic tone and morning elevation of plasma glucose levels
  619. SGLT2 inhibitors: A revolution in therapeutics of a major Non 3 Communicable Disease 4
  620. Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation
  621. Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
  622. RE: Should we stick to SGLT2 inhibitors?
  623. Role of SGLT2 inhibitors in Heart Failure
  624. P317 A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A sub-study …
  625. EUGLYCEMIC DIABETIC KETOACIDOSIS CAUSED BY SGLT2 inhibitors AND A KETOGENIC DIET: A CASE SERIES AND REVIEW OF LITERATURE
  626. SGLT2 inhibitors: a new treatment option for type 2 diabetes
  627. Development and application of a fluorescent glucose uptake assay for the high-throughput screening of non-glycoside SGLT2 inhibitors
  628. Why Are SGLT2 inhibitors Nephroprotective? Mechanisms of Action And Possible Benefits A Review
  629. Fournier’s gangrene and sodium-glucose co-transporter 2 (SGLT2) inhibitors: Our experience
  630. Utility of SGLT2 inhibitors in patients with chronic heart failure with diabetes mellitus
  631. 35-OR: Risk of Cardiovascular Outcomes in Diabetes Patients following the Addition of SGLT2 inhibitors vs. Sulfonylureas to Baseline GLP-1RA Therapy
  632. An evaluation of US patent 2015065565 (A1) for a new class of SGLT2 inhibitors for treatment 1 of type II diabetes mellitus
  633. Comparative effects of sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors on new-onset atrial fibrillation and stroke …
  634. Marked Hypertriglyceridemia in a Patient with type 2 Diabetes Receiving SGLT2 inhibitors
  635. SGLT2–inhibitors
  636. To Heart “Fail” or Not? The Expanding Role of SGLT2 inhibitors
  637. SGLT2 inhibitors: Rationale and Perspectives of Use in Heart Failure
  638. 2275-PUB: Relationship between the Effect of SGLT2 inhibitors and Dietary Intake in Japanese Patients with Type 2 Diabetes
  639. Extending the Use of SGLT2 inhibitors from Diabetic to Non-diabetic Kidney Disease
  640. Lower Risk of Death With SGLT2 inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018; 41: 6–10
  641. SGLT2 inhibitors and nephroprotection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature
  642. Lower Risk of Death With SGLT2 inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018; 41: 6–10
  643. SGLT2 inhibitors and ketoacidosis: pathophysiology and management
  644. SGLT2 inhibitors in diabetic and non-diabetic nephropathies
  645. SGLT2 inhibitors: A Noval Therapuetic Agent in the Treatment of Diabetic Kidney Disease
  646. SGLT2 inhibitors
  647. Real-life prescribing of SGLT2 inhibitors: How to handle other medications, including glucose-lowering drugs and diuretics
  648. Molecular modeling studies of thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents
  649. Cardiac Energy Metabolism and the Role of SGLT2 inhibitors in Heart Failure
  650. The position of SGLT2 inhibitors in current medicine.
  651. The Elevation of Hematocrit after Administration of SGLT2 inhibitors Does Not Correlate with Plasma Osmolarity in Japanese Subjects with Type 2 Diabetes
  652. FP499 PHARMACODYNAMIC REASON WHY THE DOSE OF SGLT2 inhibitors SHOULD NOT BE REDUCED IN PATIENTS WITH GFR LESS THAN 45 ML/MIN
  653. SGLT2 inhibitors and Heart Failure Outcomes
  654. SGLT2 inhibitors: a new therapeutic class for the treatment of type 2 diabetes mellitus
  655. gem‐Dimethyl‐bearing C‐Glucosides as Sodium‐glucose Co‐transporter 2 (SGLT2) inhibitors
  656. 163-LB: Impact of SGLT2 inhibitors on Liver Function Test in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-analysis
  657. Prolonged Glucosuria With Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors: A Case Report and Review of Literature
  658. SGLT2 inhibitors-SOMETHING IN THE WATER, OR THE HEART OF THE MATTER?
  659. EFFECT OF SGLT2 inhibitors ON LIPID PARAMETERS: A META-ANALYSIS OF 30 RANDOMIZED CLINICAL TRIALS AND 10,246 PATIENTS
  660. 1217-P: The Kidney Effects of the SGLT2 inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
  661. Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world
  662. SGLT2 inhibitors and diabetic nephropathy: sweet nothings
  663. SGLT2 inhibitors cost effective versus sulfonylureas in T2DM
  664. SGLT2 inhibitors, beyond glucose-lowering effect: impact on nephrology clinical practice
  665. Complementarity between randomised controlled trials and observational registries: the example of cardiovascular prevention with SGLT2 inhibitors
  666. Recognizing low endogenous insulin production as a precipitating factor of DKA in type-2 diabetic patients taking SGLT2 inhibitors: a case report
  667. Cost Analysis of SGLT2 inhibitors in patients with type 2 Diabetes in India
  668. Annals On Call-SGLT2 inhibitors: The Good, the Bad, and the Ugly
  669. NON-CARDIAL EFFECTS OF SGLT2 inhibitors (REVIEW)
  670. SGLT2 inhibitors
  671. SGLT2 inhibitors and their association with balanoposthitis and Fournier’s gangrene.
  672. 2340-PUB: Success of Online CME at Improving the Clinical Knowledge and Confidence in Using SGLT1/SGLT2 inhibitors in T1D Management
  673. SGLT2 inhibitors ARE NOT ASSOCIATED WITH RISKS FOR AMPUTATION-A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED …
  674. Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Stroke―Reply―
  675. EFFECTS OF SGLT2 inhibitors ON STROKE IN TYPE 2 DIABETES ACCORDING TO BASELINE KIDNEY FUNCTION
  676. The emerging role of SGLT2 inhibitors in the treatment of type 2 diabetes. Focus on dapagliflozin
  677. Spiroketal Phthalane C-Glycosides: Synthesis of Papulacandins and SGLT2 inhibitors
  678. Effects of SGLT2 inhibitors in type 2 diabetes, comparing women to men
  679. Role of sodium-glucose cotransporter 2 (SGLT2) inhibitors
  680. GLYCEMIC OUTCOMES OF SGLT2 inhibitors IN OVERWEIGHT OR OBESE TYPE 2 DIABETES PATIENTS
  681. SGLT2 inhibitors in patients with chronic kidney disease: from clinical trials to guidelines and new prospects for clinical practice
  682. 1227-P: GlycoMark 1, 5-Anhydrocluitol values in patients taking SGLT2 inhibitors
  683. Heart failure protection by SGLT2 inhibitors in patients with type 2 diabetes mellitus: evidence and possible mechanisms: A systematic review
  684. House of Carbs: the path to euglycemic DKA in patients with Diabetes on SGLT2 inhibitors
  685. Is the joint use of diuretics and SGLT2 inhibitors beneficial in diabetic kidney disease?
  686. … control and cardiovascular risk factor management in adults with type 2 diabetes with and without chronic kidney disease before SGLT2 inhibitors: Insights from the …
  687. A Comprehensive Review on various HPLC based Analytical techniques used for the Estimation of SGLT2 inhibitors type of Antidiabetic drugs in various …
  688. SGLT2 inhibitors compared with sitagliptin as add-on therapy to metformin in type 2 diabetes: a systematic review and meta-analysis
  689. … Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 inhibitors to the Improvement …
  690. Therapeutic Potential of SGLT2 inhibitors in Treating Type 2 Diabetes Mellitus
  691. Promise, peril, and possible new treatment options incurred by sodium glucose co-transporter 2 (SGLT2) inhibitors: A precise review up to 2018
  692. P272 Additional use of SGLT2 inhibitors in the treatment of acute decompensated heart failure may prevent acute kidney injury
  693. What Are The Benefits In The Association Of SGLT2 inhibitors And Other Drugs?
  694. … Ali, Muhammad Umer Ahmed, Sundas, Muhammad Aslam Khan, Qalb Khan, Gul Muhammad Memon, Izhan Ali Khan. Role of SGLT2 inhibitors in Heart Failure
  695. SGLT2 inhibitors in Patients with Diabetes and Cardiovascular Disease
  696. Minireview: are SGLT2 inhibitors heart savers in diabetes?
  697. SGLT2 inhibitors: results from clinical practice
  698. Comment on” comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in …
  699. Efficiency and safety of SGLT2 inhibitors
  700. Mechanisms and efficacy of SGLT2 inhibitors
  701. Reply to Comment: Is there any place for SGLT2–inhibitors in post-liver transplantation patients?
  702. 101 Heart failure, diabetes and use of SGLT2 inhibitors–a missed opportunity
  703. Renoprotective Effects of SGLT2 inhibitors
  704. Leaving the Glucocentric View: Can SGLT2 inhibitors Halt CVD in Patients With Type 2 Diabetes?
  705. … and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 inhibitors. Diabetes Care 2015; 38: 1638 …
  706. SGLT2 inhibitors: a focus on cardiac benefits and potential
  707. A Review on Efficacy and Safety of SGLT2 inhibitors as Add-on Therapy with Metformin
  708. Sodium glucose co-transporter 2 (SGLT2) inhibitors in type 2 diabetes: a literature review of approved products
  709. Correction to: Optimising the Benefits of SGLT2 inhibitors for Type 1 Diabetes
  710. What have we learned from clinical outcome trials with SGLT2 inhibitors?
  711. Using SGLT2 inhibitors in Special Populations
  712. The SGLT2 inhibitors-a review: original
  713. Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
  714. Sodium-glucose co-transporter 2 (SGLT2) inhibitors
  715. CLINCIAL EXPERIENCE WITH THE USE OF SODIUM GLUCOSE TRANSPORTERS SGLT2 inhibitors IN AN ENDOCRIONOLOGY OUTPATIENT CLINIC IN …
  716. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and stroke
  717. SGLT2 inhibitors, GLP-1 Receptor Agonists, or Bariatric Surgery and Risks of All-Cause Mortality, Cardiovascular Diseases, End-Stage Renal Diseases, and Severe …
  718. SGLT2 inhibitors in Diabetes mellitus
  719. SGLT2 inhibitors Continue to Show Kidney, Heart Benefits
  720. 156-OR: Risk-Benefit of SGLT2 inhibitors (SGLT2i) vs. GLP-1 Receptor Agonists (GLP-1RA) in Routine Care of Older Adults
  721. The Benefits of SGLT2 inhibitors in Cardiovascular Prevention, Glycemic Control and Weight Loss, in the Treatment of Diabetes
  722. Comparative Cardiovascular Effectiveness of SGLT2 inhibitors vs. Liraglutide in Routine Care
  723. The Role of SGLT2 inhibitors in Clinical Practice
  724. SGLT2 inhibitors and Renal Outcomes
  725. SGLT2 inhibitors for Treating Diabetes
  726. 2363-PUB: The efficacy of low vs. high FDA-approved SGLT2 inhibitor dose compared with DPP-4 inhibitors: a meta-analysis
  727. SUN-177 house of Carbs: the path to euglycemic Dka in patients with diabetes on SGLT2 inhibitors
  728. Sodium Glucose Co-transporter Type 2 (SGLT2) inhibitors in CKD
  729. PRETREATMENT WITH SGLT2 inhibitors AMELIORATES CONTRAST-INDUCED NEPHROPATHY
  730. Comprehensive evaluation of cardiovascular efficacy and safety outcomes of SGLT2 inhibitors in high risk patients of cardiovascular disease: systematic review and …
  731. Sodium-glucose cotransporter 2 inhibitors (SGLT2-I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes.
  732. Euglycemic ketoacidosis: a complication of SGLT2 inhibitors
  733. Cardioprotective and Renoprotective Effects of the Use of SGLT2 inhibitors in Diabetes Mellitus Patients
  734. Predicting the Need for SGLT2 inhibitors for Future Heart Failure
  735. Model-based meta-analysis of glucosuria-related adverse events in SGLT2 inhibitors
  736. Lower urinary tract symptoms (LUTS) in males with type 2 diabetes recently treated with SGLT2 inhibitors—overlooked and overwhelming? A retrospective case series
  737. Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
  738. SUN-181 case report: rare complication of SGLT2 inhibitors can occur only 10 days after starting the medication
  739. 2343-PUB: reduction of HbA1c after SGLT2 inhibitors correlate with change in plasma osmolarity but not with elevation of hematocrit in Japanese patients with type 2 …
  740. P2521 Cardiovascular outcomes associated with SGLT2 vs DPP4 inhibitors in type 2 diabetic patients with and without established cardiovascular diseases: a …
  741. A Significance of Sodium-Glucose Cotransporter 1 (SGLT1) Inhibition by SGLT2 inhibitors
  742. FP408 NOVEL MOLECULAR MECHANISMS IN THE RENOPROTECTIVE EFFECT OF SGLT2 inhibitors VIA MITIGATION OF TUBULAR HYPOXIA AND PROTEIN …
  743. Impact of SGLT2 inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group
  744. Combination therapy with once weekly GLP 1 receptor agonist dulaglutide and SGLT2 inhibitors in Asian Indians with type 2 diabetes
  745. … and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 inhibitors. Diabetes Care 2015; 38: 1638 …
  746. Effects of Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors on Major Cardiovascular Events in Type 2 Diabetic Patients a Meta-Analysis of Randomized …
  747. THE ROLE OF SGLT2 inhibitors IN TYPE 2 DIABETES
  748. Erratum. SGLT2 inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management. Diabetes Care 2018; 41: 1543 …
  749. Exploration of novel C-glucoside formation and application for SGLT2 inhibitors-Discovery of canagliflozin as a SGL T2 inhibitor
  750. Beware ketoacidosis with SGLT2 inhibitors in latent autoimmune diabetes.
  751. Os 32-05 Effects of SGLT2 inhibitors on circadian rhythm of blood pressure in rats
  752. 2300-PUB: The Efficacy and Safety of Combinations of SGLT2 inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: A Systematic Review and …
  753. The Use of SGLT2 inhibitors in Elderly Patients with Type 2 Diabetes Mellitus
  754. SGLT2 inhibitors: Now The Bad News
  755. A Comparison of the Effects of SGLT2 inhibitors in Heart Failure Patients with Diabetes Versus Non-diabetic Patients
  756. SGLT2 inhibitors for type 2 diabetes: Clinical considerations
  757. SGLT2 inhibitors and kidney outcomes in the real world
  758. A NOVEL ROLE OF SGLT2 inhibitors TO INCREASE CIRCULATING PROANGIOGENIC PROGENITOR CELLS IN PATIENTS WITH TYPE 2 DIABETES AND …
  759. 1, 2, 4-Triazinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors
  760. Effectiveness and safety of SGLT2 inhibitors compared to dipeptidyl peptidase (DPP)-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based …
  761. SGLT2 inhibitors in T2D and associated comorbidities-differentiating within the class: correspondence
  762. SGLT2 inhibitors Reduce Blood Pressure and Left Ventricular Mass
  763. SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
  764. The Renoprotective Effects of SGLT2 inhibitors versus Placebo in Patients with Type 2 Diabetes with or
  765. Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 inhibitors in Type 2 Diabetes Management: Key Evidence and …
  766. Comparative Cardiovascular Efficacy of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 Agonists—A Network Meta-analysis
  767. A New Weapon in the Fight Against Diabetes: SGLT2 inhibitors
  768. Assimilating the Evidence in T2DM Cardiovascular and Renal Outcomes With SGLT2 inhibitors Daniel Einhorn, MD, FACE, FACP; Serge A. Jabbour, MD, FACP …
  769. 1431-P: Risk of Venous Thromboembolism amongst Initiators of SGLT2 inhibitors Compared with Other Glucose-Lowering Agents
  770. 2218-PUB: Initiation of SGLT2 inhibitors in Hospitalized Patients with CVD
  771. Cardiovascular safety of SGLT2 inhibitors
  772. Effects and Safety of SGLT2 inhibitors on Cardiovascular and Renal Outcomes in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of …
  773. Erratum to: practical approach to initiating SGLT2 inhibitors in type 2 diabetes
  774. … Weight Reduction and Suppression of Cardiovascular Events in Recent Clinical Trials of DPP4 inhibitors, GLP-1 Receptor Agonists, and SGLT2 inhibitors
  775. Uric Acid Is a Biomarker of Oxidative Stress in the Failing Heart: Lessons Learned from Trials With Allopurinol and SGLT2 inhibitors
  776. Persistence to Treatment with DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1-RAs Compared with Insulin after Failure with First Antidiabetic Drug in T2DM Patients
  777. 1162-P: Coverage, Formulary Restrictions, and Average Retail Prices of SGLT2 inhibitors and GLP-1 Receptor Agonists across Medicare Part D Plans in 2019
  778. COMPARISON OF EFFECTIVENESS OF SGLT2 inhibitors IN THE INDIAN MULTI ETHINIC TYPE 2 DIABETES PATIENTS-REAL WORLD EXPERIENCE
  779. Bitter sweet: Fournier’s Gangrene and SGLT2 inhibitors
  780. SGLT2 inhibitors REDUCE MAJOR ADVERSE CARDIOVASCULAR EVENTS IN TYPE 2 DIABETIC PATIENTS: A META-ANALYSIS OF RANDOMIZED …
  781. SGLT2–inhibitors in the Management of Type 2 Diabetes
  782. SGLT2 inhibitors and risk of genitourinary infections
  783. The combination of GLP-1 analogs and SGLT2 inhibitors: new perspectives?
  784. Synthetic Studies towards Carbocyclic Analogues of SGLT2 inhibitors
  785. 1211-P: Real-World Use of SGLT2 inhibitors in a Large US Safety-Net Health System
  786. Two alcoholic liver cirrhosis patients developed diabetic ketoacidosis after SGLT2 inhibitors-prescription
  787. The use of SGLT2 inhibitors compared to GLP-1 receptor agonists in patients with type 2 diabetes and hypertension
  788. SGLT2 inhibitors and Ketoacidosis: Cause for Concern?
  789. SGLT2 inhibitors–Is the Paradigm in Type 2 Diabetes Mellitus Management Changing?
  790. MON-170 OUTCOMES OF SGLT2 inhibitors USE IN DIABETIC RENAL TRANSPLANT PATIENTS-SINGLE CENTER EXPERIENCE
  791. SAT-298 EFFECT OF SGLT2 inhibitors ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS …
  792. Frequently asked questions: SGLT2 inhibitors–a novel approach to managing hyperglycaemia
  793. Predictors of response to SGLT2–inhibitors and DPP4-inhibitors: a MASTERMIND stratified medicine study
  794. SGLT2 inhibitors and the Risk of Ketoacidosis in Patients With Type 2 Diabetes
  795. 172 Untold Story of SGLT2 inhibitors
  796. … of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) inhibitors: A …
  797. Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors
  798. 34-OR: SGLT2 inhibitors: A Comparison of Cardiovascular, Medical, and Cost Outcomes
  799. Glucose Lowering Effect of SGLT2 inhibitors: A Review of Clinical Studies.
  800. SGLT2 inhibitors Increase Bone Strength by Increasing Procollagen Type 1 Amino-Terminal Propeptide in Patients with Type 2 Diabetes
  801. 081 Assessment of SGLT2 inhibitors use in Heart Failure Patients at a Tertiary Hospital
  802. “The Proof is in the Pudding”: Do SGLT2 inhibitors Cause Diabetic Ketoacidosis?
  803. SGLT2 inhibitors protect against MACE, suggests meta-analysis
  804. 1200-P: Use of SGLT2 inhibitors in Hospitalized Patients in an Academic Center
  805. Real-life clinical experience with GLP1 analogs and SGLT2 inhibitors in the treatment of diabetes type 2 and obesity
  806. Meta-analysis of SGLT2 inhibitors and stroke risk in type 2 diabetic patients
  807. APPLICATION OF THE MINIMAL MODEL IN SUBJECTS TREATED WITH SGLT2 inhibitors
  808. SGLT2 inhibitors: A Novel Therapy for Type 2 Diabetes Mellitus
  809. www. OpenCME. org/course/where-do-SGLT2–inhibitors-fit-spectrum-of-treatment-of-t2dm
  810. Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three SGLT2 inhibitors in Type 2 DM Subjects
  811. Letter to the Editor: Sodium‐glucose cotransporter 2 inhibitors (SGLT2‐I) ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes
  812. Effects of SGLT2 inhibitors in the treatment of a population with type 2 diabetes mellitus
  813. Efficacy of SGLT2 inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
  814. SGLT2 inhibitors–new oral hypoglycemic drugs inhibitory SGLT2–nowe doustne leki przeciwcukrzycowe
  815. Relation Between HbA1c Level and Effectiveness of SGLT2 inhibitors in Diabetic Patients With Acute Decompensated Heart Failure
  816. SGLT2 inhibitors Associated With Lower-Extremity Amputation Among Patients With Type 2 Diabetes
  817. 137-LB: Early Performance Under SGLT2 inhibitors in High-Risk Patients: EARLY PUSH Study: A Prospective Double-Blind Comparative Study
  818. Maximizing Patient Safety with Newly Approved Therapies: Focus on SGLT2 inhibitors
  819. MHRA drug safety update: risk of Fournier’s gangrene with SGLT2 inhibitors for diabetes
  820. The Positive Effect of the Combination of GLP-1 Analogues and SGLT2 inhibitors on Obese Patients with Noninsulin-Treated DM2
  821. Letter to the Editor: Comment on “SGLT2 inhibitors may predispose to ketoacidosis” by Taylor SI, et al
  822. Lower Risk of CV Events and Death Associated with Initiation of SGLT2 vs. DPP-4 inhibitors—Analysis from the CVD-REAL 2 Study
  823. SGLT2 inhibitors as adjunct therapy to insulin in type 1 diabetes: Meta analysis
  824. The Role of SGLT2 inhibitors and DPP4 inhibitors in Preventing Diabetic Nephropathy
  825. The metabolic effects of SGLT2 inhibitors-Does the increase in ketone bodies protect the heart?
  826. Renal SGLT2 inhibitors, new agents for the management of type 2 diabetes
  827. Effect of SGLT2 inhibitors on glucagon secretion in pancreatic alpha cells
  828. Sodium-glucose co-transporter 2 (SGLT2) inhibitors renal benefits and beyond
  829. Use of Sodium-Glucose Co-Transporter-2-inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation.
  830. Sodium Glucose Cotransporter-2 inhibitors (SGLT2 inhibitors)
  831. The difference between SGLT2 and DPP-4 inhibitors on glucose fluctuation in patients with type 2 diabetes
  832. 2354-PUB: Estimating Improvement of TGF Mechanism from Changes of Urinary Glucose and Sodium Excretion by SGLT2 inhibitors
  833. Erratum to: sodium glucose co-transporter-2 (SGLT2) inhibitors: a review of their basic and clinical pharmacology
  834. Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Cardiovascular Disease: A Systematic Review
  835. Methods of producing C-aryl glucoside SGLT2 inhibitors
  836. … COTRANSPORTER-2 (SGLT2) inhibitors, GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS, DIPEPTIDYL PEPTIDASE 4 (DPP-4) inhibitors …
  837. Cover Feature: Fluorine‐Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 inhibitors for Type II Diabetes (Chem. Eur. J. 12/2018)
  838. Evaluating Drug Cost per Response with SGLT2 inhibitors in Patients with Type 2 Diabetes Mellitus
  839. An Overview On Aryl C-glycosides As SGLT2 inhibitors With Antidiabetic Potential.
  840. SGLT2 inhibitors for gout: Do these antihyperglycaemic agents reduce uric acid levels?
  841. SGLT2 inhibitors IN KETOACIDOSIS: THE CULPRIT OR AN INNOCENT BYSTANDER?
  842. Improved preparation of C-aryl glucoside SGLT2 inhibitors
  843. Efficacy and Usefulness of SGLT2 inhibitors in Niddm Patients on the Backdrop of Metformin and Sulphonyl Urea
  844. Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis
  845. 1141-P: Effects of SGLT2 inhibitors on Nighttime Sympathetic Nerve Activity, Heart Rate, Blood Pressure Variability, and Glycemic Variability in Type 2 Diabetic …
  846. ASSESSMENT OF SGLT2 inhibitors ON KIDNEY MORPHOLOGY AND ALBUMIN EXCRETION IN RATS WITH EXPERIMENTAL DIABETES MELLITUS TYPE 1.
  847. An audit of SGLT2–inhibitors in the management of type 2 diabetes in Sligo University Hospital Ireland: metabolic and haemodynamic outcomes
  848. Euglycemic diabetic ketoacidosis in type 2-diabetes mellitus treated with SGLT2 inhibitors-a report on two cases
  849. SGLT2 inhibitors for Type 2 Diabetes Mellitus Treatment SGLT2 inhibitors are plausible second-line drugs that provide powerful additional A1c-lowering …
  850. Incidence of Heart Failure Hospital Admissions Among Type 2 Diabetes Mellitus Patients and the Potential Impact of SGLT2 inhibitors in Japan: A Population-based …
  851. A survey of various adjuvant treatments used against type 1 diabetes, focusing on SGLT2 inhibitors
  852. Potential Unrealized Mortality Benefit of GLP-1 Receptor Agonists and SGLT2 inhibitors: A Report from the Veterans Health Administration Clinical Assessment …
  853. Cardiorenal protection with SGLT2 inhibitors (gliflozins): from EMPA-REG OUTCOME to CANVAS
  854. Prevalence of psychiatric comorbidities in diabetic patients who are candidates for therapy with SGLT2 inhibitors: clinical and metabolic characteristics
  855. Meet the SGLT2 inhibitors: these new type 2 diabetes medications block glucose reabsorption by the kidneys
  856. Disparities in the prescribing of DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 analogues in UK primary care
  857. 2350-PUB: Renoprotective Effects of SGLT2 inhibitors in Japanese Real-World Clinical Practice
  858. 1433-P: Protective Effect of GLP-1 Receptor Agonists (GLP-1 RA) and SGLT2 inhibitors (SGLT2i) against Adverse Cardiovascular (CV) Events in HIV and Type 2 …
  859. FP451 SIGNIFICANCE OF RENAL AUTONOMIC NERVES FOR WEIGHT-REDUCTION BY SGLT2 inhibitors
  860. 676-P: Ideal Ketone Test Training among Type 1 Patients in Context of Risk Associated with SGLT2 inhibitors
  861. Case of Euglycemic Ketoacidosis Induced by SGLT2 inhibitors (Sodium-Glucose Cotransporter 2) in a Diabetic Patient
  862. Comparative Effectiveness of SGLT2 inhibitors vs. Sitagliptin Add-on Therapy to Metformin inType-2 Diabetes
  863. 247-OR: Real-World Effectiveness of SGLT2 inhibitors vs. GLP-1 Receptor Agonists in Patients With and Without Cardiovascular Disease
  864. Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors and their role in Type 1 Diabetes
  865. Evolving physicians’ perceptions and practices regarding use of SGLT2 inhibitors for type 2 diabetes during Ramadan fasting
  866. 1115-P: Comparative Rate of Amputations among Type 2 Diabetes Patients Starting Different SGLT2 inhibitors
  867. Rates of myocardial infarction and stroke in patients initiated on SGLT2–inhibitors versus other glucose-lowering agents in real-world clinical practice: results …
  868. REVIEW OF EFFICACY AND SHORT TERM SAFETY OF SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT2) inhibitors USE IN DIABETIC RENAL TRANSPLANT …
  869. Potential Harmful Effects of The Novel Anti-Diabetics, inhibitors of Sodium-Glucose Cotransporters SGLT1 and SGLT2
  870. 12-month effects of incretins versus SGLT2–inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 …
  871. Combination therapy of SGLT2 inhibitors with incretin-based therapies for the treatment of type 2 diabetes mellitus: Effects and mechanisms of action
  872. 1962-P: Comparison of the Effects of Three SGLT2 inhibitors on Metabolic Parameters and Insulin Sensitivity in a Nondiabetic Rat Model of Metabolic Syndrome
  873. 2347-PUB: Relationship between Aging and Effects of SGLT2 inhibitors on Glucose and Lipid Metabolisms and Hepatic Function in Japanese Patients with Type 2 …
  874. OR22-1 Liraglutide as Add-on to SGLT2 inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (LIRA-ADD2SGLT2i): A 26-Week, Randomized, Double …
  875. SUN-155 Clinical Experience of SGLT2 inhibitors in a Hispanic Population: Should We Consider Its Use as Add-On Treatment?
  876. … therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium–glucose cotransporter 2) inhibitors
  877. Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (SGLT2) inhibitors
  878. Control of Blood Glucose with Sodium Glucose Co-transporter 2 (SGLT2) inhibitors Among Patients with Type 2 Diabetes Mellitus
  879. Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors: Comparing Trial and Real World Use (Study Protocol)
  880. Sodium Glucose Cotransporter 2 (SGLT2) inhibitors: New drug class in the treatment of Heart Failure with Reduced Ejection Fraction—DAPA-HF and …
  881. COMPARATIVE EFFICACY OF 3 SGLT2 inhibitors AS THE FIFTH DRUG IN THE MANAGEMENT OF TYPE 2 DM IN ASIAN INDIANS NOT CONTROLLED WITH …
  882. 25-LB: SGLT2 inhibitors Are Renoprotective via Mitigation of Tubular Hypoxia and Protein O-GlcNAcylation
  883. Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors Drug Class Review
  884. Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention …
  885. … in type 2 diabetes: harnessing individual-level trial data alongside routine care records to identify predictors of response to SGLT2 inhibitors and DPP4 inhibitors
  886. Health Expenditure Comparison of Diabetic Patients on Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors Vs Dipeptidyl Peptidase-4 (DPP4) inhibitors
  887. Type 2 Diabetes, SGLT2 inhibitors, and Glucose Secretion
  888. National prevalence of heart failure in type 2 diabetes patients derived from the National eHealth System and their access to treatment with SGLT2 inhibitors or GLP-1 …
  889. Class Update: Sodium-glucose Cotransporter 2 (SGLT2) inhibitors
  890. [PP. 05.19] EFFECTS OF SGLT2 inhibitors ON BLOOD PRESSURE, BAPWV, CAROTID ARTERIAL IMT AND ELASTIC MODULUS IN TYPE 2 DIABETIC …
  891. The efficacy and safety of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
  892. Non-severe hypoglycemia risk difference between sulfonylurea and sodium-glucose cotransporter-2 inhibitors (SGLT2-I) as an add-on to metformin in …
  893. Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or …
  894. Erratum to: Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Cardiovascular Disease: A Systematic
  895. SYSTEMATIC REVIEW OF SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) inhibitors IN THE TREATMENT FOR PATIENTS WITH DIABETES …
  896. Sodium Glucose Co transporter 2 (SGLT2) inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus
  897. … of autonomous aldosterone secretion in patients with type 2 Diabetes Mellitus and arterial hypertension. The effect of SGLT2 inhibitors on renin-angiotensin …
  898. A Five Featured Pharmacophore Model for the Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) inhibitors
  899. SY 10-3 SGLT2 inhibitors AS POTENTIAL ANTIHYPERTENSIVE AND RENOPROTECTIVE AGENTS
  900. SY 10-2 THE ROLE OF SGLT2 inhibitors IN THE MANAGEMENT OF T2DM
  901. PS 11-73 BLOOD PRESSURE AND BODY WEIGHT LOWERING EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORT 2 (SGLT2) inhibitors.
  902. The position of new antidiabetics in clinical practice: SGLT2 vs DPP4 inhibitors
  903. 5, 5-Difluoro-and 5-Fluoro-5-methyl-hexose-based C-Glucosides as potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors
  904. Systematic Review of SGLT2 Receptor inhibitors in dual or triple therapy in type 2 diabetes
  905. SGLT2 versus DPP4 inhibitors for Type 2 Diabetes: A Meta-analysis
  906. Audit on sodium glucose cotransporter-2 inhibitors (SGLT2) at Nottingham University Hospitals
  907. Empagliflozin-the new representative of SGLT2 transporter inhibitors for the treatment of patients with diabetes 2 type

 

Related Posts

Shopping Cart
Scroll to Top